 Two-drug therapy patients metastatic germ cell tumors Eighty-two patients metastatic germ cell tumors GCT two-drug therapy consisting etoposide cisplatin late relapse Good-risk GCT Memorial Sloan-Kettering Cancer Center MSKCC criteria Etoposide days cisplatin days therapy days delays days leukocyte count platelet count Drug doses myelosuppression Seventy-six evaluable patients complete response CR Seventy-two patients CR Forty-six patients excision residual abnormalities resected specimen necrotic debris fibrosis CR chemotherapy complete excision residual viable GCT Six patients incomplete response chemotherapy patients unresectable mature teratoma progression-free median etoposide dose standard deviation SD median cisplatin dose SD Nine patients relapse months patients nonseminomatous GCT chemotherapy patient seminoma chemotherapy radiation therapy patients additional therapy disease-free months patients disease-free median follow-up time months range months relapses months Etoposide cisplatin therapy doses schedule results durable CR late relapse